Semaglutide: The Chemistry of a Long-Acting Peptide
Three modifications turn a peptide with a two-minute half-life into one measured in days. A worked example of half-life engineering.
Semaglutide is a 31-residue peptide built on the human GLP-1 backbone, and it is one of the clearest worked examples of half-life engineering in peptide chemistry. Three deliberate modifications turn a molecule with a circulating half-life of minutes into one measured in days.
The starting point
The parent is human GLP-1(7–37), an incretin peptide. In its native form it is degraded almost immediately — dipeptidyl peptidase-4 cleaves after the alanine at position 8, and that cleavage destroys receptor activity. Native GLP-1 has a half-life of roughly two minutes.
Any useful analogue therefore has to solve two separate problems: enzymatic cleavage, and renal clearance of a small molecule.
The three modifications
1. Aib at position 8
Alanine at position 8 is replaced with α-aminoisobutyric acid, a non-proteinogenic residue with two methyl groups on the alpha carbon. DPP-4 cannot accommodate the additional bulk, so the cleavage that ends native GLP-1’s activity does not occur.
2. Lys34Arg
The lysine at position 34 is substituted with arginine. This is not a stability change — it removes a second lysine so that the acylation in step three attaches at one defined position rather than two. It is a chemistry-control substitution, and it is why the product is a single defined molecule rather than a mixture of regioisomers.
3. Fatty diacid acylation at Lys26
The remaining lysine carries a C18 fatty diacid attached through a linker of γ-glutamic acid and two units of AEEA (8-amino-3,6-dioxaoctanoic acid).
The fatty acid binds reversibly to serum albumin. Albumin is large, long-lived and not filtered by the kidney, so a peptide associated with it is effectively hidden from renal clearance and released slowly as the equilibrium shifts. The hydrophilic AEEA spacer holds the fatty acid far enough from the peptide that receptor binding is not obstructed.
This is the modification that produces the week-long half-life. The Aib substitution stops the enzyme; the acylation stops the kidney.
What this means analytically
Semaglutide is a demanding molecule to characterise, and the certificate should reflect that:
- Molecular weight is approximately 4113 g/mol. A mass corresponding to the unacylated peptide would indicate the side chain is absent — the difference is not subtle.
- Thirty-one residues plus a multi-step side-chain conjugation means many synthetic steps, and deletion sequences are the expected impurity class.
- Mass spectrometry is not optional here. HPLC alone cannot confirm that the acylation is present, complete and in the right place. Identity confirmation carries most of the weight.
- Purity above 99 per cent on a molecule of this complexity is a meaningfully harder claim than 99 per cent on a pentapeptide, and should be read that way.
Handling
The amphiphilic character introduced by the fatty acid makes surface adsorption and interface-driven aggregation more relevant than for a simple hydrophilic peptide. Swirl rather than shake, avoid unnecessary headspace, and use low-binding tubes for dilute solutions. Otherwise standard practice applies: equilibrate cold vials before opening, refrigerate after reconstitution, avoid freeze–thaw cycling.
Our purity verification guide covers HPLC and mass spectrometry, and the aggregation note covers the interface problem.
Semaglutide is supplied strictly for laboratory research. We do not provide dosing information and nothing here describes use in humans. Every batch is analysed by an independent laboratory for HPLC purity and mass-spectrometric identity, with batch-matched certificates available on request.
All products and information referenced are for in-vitro research and laboratory use only. Nothing here is medical advice, and no therapeutic claim is made or implied.